Formosa Pharmaceuticals, Inc. (TPE:6838)

Market Cap	3.90B -29.5%
Revenue (ttm)	9.50M -93.4%
Net Income	-83.57M
EPS	-0.55
Shares Out	150.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	190,201
Average Volume	216,906
Open	26.05
Previous Close	25.85
Day's Range	25.85 - 26.20
52-Week Range	21.55 - 43.45
Beta	0.97
RSI	42.29
Earnings Date	May 8, 2026

About Formosa Pharmaceuticals

Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007 that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 10
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6838

Financial Performance

In 2025, Formosa Pharmaceuticals's revenue was 9.50 million, a decrease of -93.38% compared to the previous year's 143.36 million. Losses were -83.57 million, -58.43% less than in 2024.